Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Biogen Inc. (NASDAQ: BIIB).

Full DD Report for BIIB

You must become a subscriber to view this report.


Recent News from (NASDAQ: BIIB)

Scholar Rock Readies $75 Million IPO
Quick Take Scholar Rock Holding ( SRRK ) intends to raise $75 million in an IPO of its common stock, according to an SEC regulatory filing . The company is advancing a pipeline of drug treatment candidates for muscle-wasting and cancer diseases. While SRRK has a promising collaboratio...
Source: SeekingAlpha
Date: May, 15 2018 13:01
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Trump speech on drug prices light on specifics
Key points from President Trump's speech detailing his plan to lower U.S. drug prices called American Patients First: More news on: Health Care Select Sect SPDR ETF, Vanguard Health Care ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 14:25
Trump plan on drug prices to be announced this afternoon
President Trump is set to announce his plan to corral drug prices in a speech set to begin at 2:00 pm ET today. According to administration officials the plan will not include a call to Congress to allow Medicare to negotiate drug prices, a move currently prohibited under federal law. Mo...
Source: SeekingAlpha
Date: May, 11 2018 10:22
FANG Stocks Have Ignited A Rally - Cramer's Mad Money (5/10/18)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 10. The market has been seeing negativity and selloff in the recent past. However, the non-believers have been converted to believers now. How did this happen? All it took was great earnings...
Source: SeekingAlpha
Date: May, 11 2018 07:38
Our Free Research Report on Biogen and More Biotech Stocks
Stock Research Monitor: AVXS, BHVN, and BMRN LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on BIIB sign up now at www.wallstequities.com/registration . On Tuesday, May 08, 2018, US markets saw four out of nine sectors finishing the day in green, four in re...
Source: ACCESSWIRE IA
Date: May, 09 2018 07:35
Biogen Celebrates 40 Years as a Pioneer in Neuroscience
Members of the Media are Invited to Join Us for Our 40 th Anniversary Event “Biogen in Neuroscience: Past, Present & Future” Biogen (Nasdaq:BIIB): Who/What: On Monday, May 14, 2018, Biogen (Nasdaq: BIIB), one of the world’s first global bio...
Source: Business Wire
Date: May, 07 2018 09:00
Scholar Rock Seeks $75 Million In U.S. IPO
Quick Take Scholar Rock (SRRK) intends to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a preclinical firm developing treatments for muscle-wasting and diseases and cancers. SRRK is well-funded and has a promising collaborati...
Source: SeekingAlpha
Date: May, 04 2018 14:01
Actinium Pharmaceuticals: Neglected Assets In Niche Oncology
Opportunity The best opportunities for outsized gains in biotech tend to be found in companies that are left-for-dead and/or misunderstood by market participants. However, due to the market's propensity for self-reinforcing dynamics, it can be challenging for contrarian investors to catch a ...
Source: SeekingAlpha
Date: May, 04 2018 05:00
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17280.26280.57281.62277.261,830,683
2018-05-11274.36282.39283.59274.361,908,861
2018-05-10272.65274.00276.26272.101,416,613
2018-05-09269.75274.03275.72269.071,377,304
2018-05-08271.11269.73271.45267.891,303,265

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1345,873180,25925.4484Cover
2018-08-1064,071258,73924.7628Cover
2018-08-09102,569279,14836.7436Short
2018-08-0865,206202,83832.1468Cover
2018-08-07144,764353,92540.9025Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIIB.


About Biogen Inc. (NASDAQ: BIIB)

Logo for Biogen Inc. (NASDAQ: BIIB)

Not available

 

Contact Information

 

 

Current Management

  • Thomas J. Bucknum / Secretary

Current Share Structure

  • Market Cap: $59,575,983,191 - 05/14/2018
  • Issue and Outstanding: 211,007,945 - 04/20/2018

 


Recent Filings from (NASDAQ: BIIB)

Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 24 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 01 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 25 2018

 

 


Daily Technical Chart for (NASDAQ: BIIB)

Daily Technical Chart for (NASDAQ: BIIB)


Stay tuned for daily updates and more on (NASDAQ: BIIB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BIIB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIIB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BIIB and does not buy, sell, or trade any shares of BIIB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/